C92.60

Clinical Causes: Genetic mutations involving the 11q23 region of chromosome 11. Chromosomal translocations, such as the MLL gene rearrangements, are common causes. Environmental factors and prior exposure to certain chemotherapy agents or radiation therapy, though less common, may contribute. Inherited predispositions, though rare, can also play a role.

Key Symptoms: Fatigue and weakness Unexplained weight loss Frequent or severe infections due to impaired immune function Easy bruising or bleeding, such as bleeding gums or petechiae Fever and night sweats Bone or joint pain Shortness of breath or paleness

Diagnosis Path: Complete blood count (CBC): Often reveals anemia, low white blood cell count, or abnormal cells. Bone marrow biopsy: Assesses the presence of abnormal myeloblasts and confirms the diagnosis. Cytogenetic testing: Detects specific chromosomal abnormalities involving 11q23. Molecular testing: Identifies genetic rearrangements like MLL gene translocations, which are characteristic of this subtype. Additional tests may include flow cytometry and immunophenotyping to further characterize the leukemia cells.

Treatment Protocols: Induction chemotherapy: Usually involves aggressive combinations of cytarabine and anthracyclines aimed at destroying leukemia cells. Targeted therapies: Emerging options are being studied for specific genetic abnormalities, but currently standard chemotherapy remains primary. Allogeneic stem cell transplantation: Considered in eligible patients to replace diseased marrow with healthy donor cells, especially in cases resistant to initial treatment. Supportive care: Includes blood transfusions, antibiotics, and managing side effects to support quality of life during aggressive treatment. Clinical trials: Participation in trials exploring new treatments and targeted therapies may be recommended due to the aggressive nature of this leukemia subtype.